Stone Pharmaceutical Group: 2018 innovative product performance of 10 billion, growth of 57.2%!

original title: Stone Pharmaceutical Group: 2018 innovative product performance broke 10 billion, an increase of 57.2%!key read:"Stock Market Focus" Stone Medicine have bought over the years what medicine?March 18, 2019,Stone Pharmaceutical Group Limited(HKEx Stock Code: 01093) ("Stone Pharmaceutical Group" or "Group") is pleased to announce its results for the full year ended December 31, 2018 ("This Year")In the year to review, the Group recorded sales revenue of approximately HK$21,029 million, up 36.0% YoY, while shareholders' profit stake was approximately HK$3.655 billion, up 31.9% YoYBasic earnings per share were HK$58.55The Board recommended a final dividend of HK$18 per shareInyears, the gradual in-depth national medical reform and the full implementation of the new medical insurance catalogue have enhanced the market space of the Group's innovative pharmaceutical productsThe Group has rapidly expanded its sales force, strengthened academic promotion and accelerated the development of key cities and key hospital markets, while sinking the areas of market terminal development into county hospitals and community medical institutionsAs a result of these efforts,innovative pharmaceutical products continued to grow strongly, achieving sales of HK$10,344 million in 2018, up 57.2% year-on-yearAmong them, the sales revenue of the oncology drug series increased by 123.3 percent, becoming the main growth driverthe general drug business, the Group continues to implement strategies to optimize the sales structure, increase the promotion of non-antibiotic drugs and expand the oral product line for chronic diseasesIn addition, the Group actively promotes the evaluation of the quality and efficacy of generic drugs During the year, sales of generic products maintained an ideal growth rate, achieving sales revenue of HK$6.209 billion, up 29.6% YoY api, the market supply of vitamin C was constrained by environmental pressures, providing opportunities for strong producers of large vitamin C, resulting in an excellent year for the business The operating environment for caffeine remained stable and the overall business continued to record a stable performance research and development, the Group continued to increase investment during the year, is currently researching more than 300 new products, mainly concentrated in cardiovascular, metabolic diseases (such as diabetes), anti-tumor, psycho-nervous and anti-infection areas Among them, there are 30 new target macromolecule biologic drugs, 40 new small molecule drugs and 3 new drugs of primary drugs (now new classification of 3 or 4 types of drugs) 55 , 10 and 2 small molecule new drugs are currently being clinically studied in China and the United States, 7 new macromolecule drugs (including "anti-CD20 monoclonal antibody injection", "anti-EGFR monoclonal antibody injection", "anti-RANKL monoclonal antibody injection" and two double anti-resistance products) are undergoing clinical studies in China, and four new formulation varieties (including "mitochondria liposuction injection") are undergoing clinical studies in China in addition , the Group has 26 generic drugs to be produced for approval, including "hydrochloric acid nieddaron tablets", "hydrochlorida chlorpyrifos tablets", "injectable mesocin B cholesterol sulphate compound" (new formulation drugs), "sacobic praxo tablets" and "Sakububa queritin satan sodium tablets"; U.S ANDA drugs to be approved; in addition, "Mitochonthydrohydrohydrohydrohydrolipid fluid injections", antibody drug conjugate "DP303c", "butyl benzene softgel" (indications: amyotrophic lateral sclerosis) and "ALMB-0166" have been issued in the United States to the eligibility of orphan drugs the Group continues to increase its investment in biopharmaceutical pipelines and small molecule innovative drugs In addition to in-house research and development investment, the Group is also actively looking for external opportunities for cooperation and acquisition In the year and recently completed a number of cooperation or acquisition projects, further improve the layout of the research and development pipeline The Group's acquisition focuses on new new molecular drugs of the size to be approved for marketing in order to replenish the new drug reserves to be launched in the coming years as soon as possible and to take full advantage of the Group's strong marketing and market development capabilities to achieve rapid growth in new product sales